184 related articles for article (PubMed ID: 35978148)
1. Formulation Excipients and Their Role in Insulin Stability and Association State in Formulation.
Maikawa CL; Nguyen LT; Mann JL; Appel EA
Pharm Res; 2022 Nov; 39(11):2721-2728. PubMed ID: 35978148
[TBL] [Abstract][Full Text] [Related]
2. An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients.
Mann JL; Maikawa CL; Smith AAA; Grosskopf AK; Baker SW; Roth GA; Meis CM; Gale EC; Liong CS; Correa S; Chan D; Stapleton LM; Yu AC; Muir B; Howard S; Postma A; Appel EA
Sci Transl Med; 2020 Jul; 12(550):. PubMed ID: 32611683
[TBL] [Abstract][Full Text] [Related]
3. Stable Monomeric Insulin Formulations Enabled by Supramolecular PEGylation of Insulin Analogues.
Maikawa CL; Smith AAA; Zou L; Meis CM; Mann JL; Webber MJ; Appel EA
Adv Ther (Weinh); 2020 Jan; 3(1):. PubMed ID: 32190729
[TBL] [Abstract][Full Text] [Related]
4. Photoacoustic imaging reveals mechanisms of rapid-acting insulin formulations dynamics at the injection site.
Khadria A; Paavola CD; Maslov K; Valenzuela FA; Sperry AE; Cox AL; Cao R; Shi J; Brown-Augsburger PL; Lozano E; Blankenship RL; Majumdar R; Bradley SA; Beals JM; Oladipupo SS; Wang LV
Mol Metab; 2022 Aug; 62():101522. PubMed ID: 35671972
[TBL] [Abstract][Full Text] [Related]
5. Effects of phenol and meta-cresol depletion on insulin analog stability at physiological temperature.
Teska BM; Alarcón J; Pettis RJ; Randolph TW; Carpenter JF
J Pharm Sci; 2014 Aug; 103(8):2255-67. PubMed ID: 24909933
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic fibrillation of fast-acting insulin analogs.
Woods RJ; Alarcón J; McVey E; Pettis RJ
J Diabetes Sci Technol; 2012 Mar; 6(2):265-76. PubMed ID: 22538135
[TBL] [Abstract][Full Text] [Related]
7. Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical Formulation.
Gast K; Schüler A; Wolff M; Thalhammer A; Berchtold H; Nagel N; Lenherr G; Hauck G; Seckler R
Pharm Res; 2017 Nov; 34(11):2270-2286. PubMed ID: 28762200
[TBL] [Abstract][Full Text] [Related]
8. Ultra-rapid absorption of recombinant human insulin induced by zinc chelation and surface charge masking.
Pohl R; Hauser R; Li M; De Souza E; Feldstein R; Seibert R; Ozhan K; Kashyap N; Steiner S
J Diabetes Sci Technol; 2012 Jul; 6(4):755-63. PubMed ID: 22920799
[TBL] [Abstract][Full Text] [Related]
9. Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient.
Klich JH; Kasse CM; Mann JL; Huang Y; d'Aquino AI; Grosskopf AK; Baillet J; Fuller GG; Appel EA
Adv Ther (Weinh); 2023 Jan; 6(1):. PubMed ID: 36684707
[TBL] [Abstract][Full Text] [Related]
10. Profiling Insulin Oligomeric States by
Falk BT; Liang Y; McCoy MA
J Pharm Sci; 2020 Jan; 109(1):922-926. PubMed ID: 31449814
[TBL] [Abstract][Full Text] [Related]
11. Self-association properties of monomeric insulin analogs under formulation conditions.
Richards JP; Stickelmeyer MP; Flora DB; Chance RE; Frank BH; DeFelippis MR
Pharm Res; 1998 Sep; 15(9):1434-41. PubMed ID: 9755897
[TBL] [Abstract][Full Text] [Related]
12. A review of a family of ultra-rapid-acting insulins: formulation development.
Krasner A; Pohl R; Simms P; Pichotta P; Hauser R; De Souza E
J Diabetes Sci Technol; 2012 Jul; 6(4):786-96. PubMed ID: 22920803
[TBL] [Abstract][Full Text] [Related]
13. Stability of U-10 and U-50 dilutions of insulin lispro.
Stickelmeyer MP; Graf CJ; Frank BH; Ballard RL; Storms SM
Diabetes Technol Ther; 2000; 2(1):61-6. PubMed ID: 11467323
[TBL] [Abstract][Full Text] [Related]
14. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion.
DeFelippis MR; Bell MA; Heyob JA; Storms SM
Diabetes Technol Ther; 2006 Jun; 8(3):358-68. PubMed ID: 16800757
[TBL] [Abstract][Full Text] [Related]
15. The molecular chaperone alpha-crystallin as an excipient in an insulin formulation.
Rasmussen T; Tantipolphan R; van de Weert M; Jiskoot W
Pharm Res; 2010 Jul; 27(7):1337-47. PubMed ID: 20333453
[TBL] [Abstract][Full Text] [Related]
16. Chemical stability of insulin. 3. Influence of excipients, formulation, and pH.
Brange J; Langkjaer L
Acta Pharm Nord; 1992; 4(3):149-58. PubMed ID: 1418641
[TBL] [Abstract][Full Text] [Related]
17. Combining crystalline and polymeric excipients in API solid dispersions - Opportunity or risk?
Veith H; Wiechert F; Luebbert C; Sadowski G
Eur J Pharm Biopharm; 2021 Jan; 158():323-335. PubMed ID: 33296719
[TBL] [Abstract][Full Text] [Related]
18. Selective Stabilization and Destabilization of Protein Domains in Tissue-Type Plasminogen Activator Using Formulation Excipients.
Robinson MJ; Matejtschuk P; Longstaff C; Dalby PA
Mol Pharm; 2019 Feb; 16(2):744-755. PubMed ID: 30565948
[TBL] [Abstract][Full Text] [Related]
19. Binding of excipients is a poor predictor for aggregation kinetics of biopharmaceutical proteins.
Zalar M; Svilenov HL; Golovanov AP
Eur J Pharm Biopharm; 2020 Jun; 151():127-136. PubMed ID: 32283214
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol as a nontoxic excipient stabilizes insulin in a bioactive hexameric form.
Pathak BK; Das D; Bhakta S; Chakrabarti P; Sengupta J
J Comput Aided Mol Des; 2020 Aug; 34(8):915-927. PubMed ID: 32270361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
